Cryptococcal meningitis: epidemiology and therapeutic options

References

• LealALFaganelloJFuentefriaAMBoldoJTBassanesiMCVainsteinMHEpidemiological profile of cryptococcal meningitis patients in Rio Grande do Sul, BrazilMycopathologia2008166717518443922
   PubMed Web of Science ®Google Scholar
• PyrgosVSeitzAESteinerCAPrevotsDRWilliamsonPREpidemiology of cryptococcal meningitis in the US: 1997–2009PLoS One20138e5626923457543
   PubMed Web of Science ®Google Scholar
• ParkBJWannemuehlerKAMarstonBJGovenderNPappasPGChillerTMEstimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDSAIDS20092352553019182676
   PubMed Web of Science ®Google Scholar
• PerfectJRDismukesWEDromerFClinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of AmericaClin Infect Dis20105029132220047480
   PubMed Web of Science ®Google Scholar
• BrizendineKDBaddleyJWPappasPGPredictors of mortality and differences in clinical features among patients with cryptococcosis according to immune statusPLoS One20138e6043123555970
   PubMed Web of Science ®Google Scholar
• ByrnesEJ3rdBartlettKHPerfectJRHeitmanJCryptococcus gattii: an emerging fungal pathogen infecting humans and animalsMicrobes Infect20111389590721684347
   PubMed Web of Science ®Google Scholar
• SanfeliceFSull’azione patogena dei bastomiceti [On the action of pathogenic bastomiceti]Ann Isto Igiene R Univ Roma18955239262 Italian
   Google Scholar
• SanfeliceFContributo alle morfologia e biologia dei blastomiceti che si sviluppano nei succhi di alcuni frutti [Contribution to the morphology and biology of blastomiceti developing in some fruit juices]Ann Isto Igiene R Univ Roma18944463495 Italian
   Google Scholar
• FranzotSPSalkinifCasadevallACryptococcus neoformans var grubii: separate varietal status for Cryptococcus neoformans serotype A isolatesJ Clin Microbiol1999378388409986871
   PubMed Web of Science ®Google Scholar
• DromerFMathoulinSDupontBLetenneurLRoninOIndividual and environmental factors associated with infection due to Cryptococcus neoformans serotype D. French Cryptococcosis Study GroupClin Infect Dis19962391968816135
   PubMed Web of Science ®Google Scholar
• TortoranoAMVivianiMARigoniALCogliatiMRoverselliAPaganoAPrevalence of serotype D in Cryptococcus neoformans isolates from HIV positive and HIV negative patients in ItalyMycoses1997402973029476513
   PubMed Web of Science ®Google Scholar
• AntinoriSNew Insights into HIV/AIDS-associated cryptococcosisISRN AIDS2013201347136324052889
   PubMedGoogle Scholar
• Kwon-ChungKJBennettJEEpidemiologic differences between the two varieties of Cryptococcus neoformansAm J Epidemiol19841201231306377880
   PubMed Web of Science ®Google Scholar
• PappasPGPerfectJRCloudGACryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapyClin Infect Dis20013369069911477526
   PubMed Web of Science ®Google Scholar
• LuiGLeeNIpMCryptococcosis in apparently immunocompetent patientsQJM20069914315116504989
   PubMed Web of Science ®Google Scholar
• VelagapudiRHsuehYPGeunes-BoyerSWrightJRHeitmanJSpores as infectious propagules of Cryptococcus neoformansInfect Immun2009774345435519620339
   PubMed Web of Science ®Google Scholar
• MitchellDHSorrellTCAllworthAMCryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcomeClin Infect Dis1995206116167756484
   PubMed Web of Science ®Google Scholar
• SpeedBDuntDClinical and host differences between infections with the two varieties of Cryptococcus neoformansClin Infect Dis1995212834 discussion 5–67578756
   PubMed Web of Science ®Google Scholar
• ChenSCSlavinMAHeathCHClinical manifestations of Cryptococcus gattii infection: determinants of neurological sequelae and deathClin Infect Dis20125578979822670042
   PubMed Web of Science ®Google Scholar
• SukroongreungSNilakulCRuangsomboonOChuakulWEampokalapBSerotypes of Cryptococcus neoformans isolated from patients prior to and during the AIDS era in ThailandMycopathologia199613575789063001
   PubMed Web of Science ®Google Scholar
• FisherDBurrowJLoDCurrieBCryptococcus neoformans in tropical northern Australia: predominantly variant gattii with good outcomesAust N Z J Med1993236786828141697
   PubMedGoogle Scholar
• EllisDHCryptococcus neoformans var gattii in AustraliaJ Clin Microbiol1987254304313546370
   PubMed Web of Science ®Google Scholar
• SeatonRAThe management of cryptococcal meningitis in Papua New GuineaP N G Med J19963967739522853
   PubMedGoogle Scholar
• SeatonRAHamiltonAJHayRJWarrellDAExposure to Cryptococcus neoformans var gattii – a seroepidemiological studyTrans R Soc Trop Med Hyg1996905085128944257
   PubMed Web of Science ®Google Scholar
• LaurensonIFLallooDGNaraqiSCryptococcus neoformans in Papua New Guinea: a common pathogen but an elusive sourceJ Med Vet Mycol1997354374409467113
   PubMedGoogle Scholar
• LaurensonIFTrevettAJLallooDGMeningitis caused by Cryptococcus neoformans var gattii and var. neoformans in Papua New GuineaTrans R Soc Trop Med Hyg19969057608730314
   PubMed Web of Science ®Google Scholar
• KiddSEHagenFTscharkeRLA rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada)Proc Natl Acad Sci U S A2004101172581726315572442
   PubMed Web of Science ®Google Scholar
• FraserJAGilesSSWeninkECSame-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreakNature20054371360136416222245
   PubMed Web of Science ®Google Scholar
• DattaKBartlettKHBaerRSpread of Cryptococcus gattii into Pacific Northwest region of the United StatesEmerg Infect Dis2009151185119119757550
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and PreventionEmergence of Cryptococcus gattii – Pacific Northwest, 2004–2010MMWR Morb Mortal Wkly Rep20105986586820651641
   PubMedGoogle Scholar
• BartlettKHChengPYDuncanCA decade of experience: Cryptococcus gattii in British ColumbiaMycopathologia201217331131921960040
   PubMed Web of Science ®Google Scholar
• UptonAFraserJAKiddSEFirst contemporary case of human infection with Cryptococcus gattii in Puget Sound: evidence for spread of the Vancouver Island outbreakJ Clin Microbiol2007453086308817596366
   PubMed Web of Science ®Google Scholar
• BrandtMEHutwagnerLCKlugLAMolecular subtype distribution of Cryptococcus neoformans in four areas of the United States. Cryptococcal Disease Active Surveillance GroupJ Clin Microbiol1996349129178815107
   PubMed Web of Science ®Google Scholar
• KarstaedtASCrewe-BrownHHDromerFCryptococcal meningitis caused by Cryptococcus neoformans var gattii, serotype C, in AIDS patients in Soweto, South AfricaMed Mycol20024071111860015
   PubMed Web of Science ®Google Scholar
• McCarthyKMMorganJWannemuehlerKAPopulation-based surveillance for cryptococcosis in an antiretroviral-naive South African province with a high HIV seroprevalenceAIDS2006202199220617086060
   PubMed Web of Science ®Google Scholar
• SteeleKTThakurRNthobatsangRSteenhoffAPBissonGPIn-hospital mortality of HIV-infected cryptococcal meningitis patients with C. gattii and C. neoformans infection in Gaborone, BotswanaMed Mycol2010481112111520438294
   PubMed Web of Science ®Google Scholar
• LitvintsevaAPThakurRRellerLBMitchellTGPrevalence of clinical isolates of Cryptococcus gattii serotype C among patients with AIDS in sub-Saharan AfricaJ Infect Dis200519288889216088839
   PubMed Web of Science ®Google Scholar
• PfeifferTJEllisDHEnvironmental isolation of Cryptococcus neoformans var gattii from Eucalyptus tereticornisJ Med Vet Mycol1992304074081469544
   PubMedGoogle Scholar
• BartlettKHKiddSEKronstadJWThe emergence of Cryptococcus gattii in British Columbia and the Pacific NorthwestCurr Infect Dis Rep200810586518377817
   PubMedGoogle Scholar
• MacDougallLKiddSEGalanisESpread of Cryptococcus gattii in British Columbia, Canada, and detection in the Pacific Northwest, USAEmerg Infect Dis200713425017370514
   PubMed Web of Science ®Google Scholar
• DromerFMathoulin-PelissierSFontanetARoninODupontBLortholaryOEpidemiology of HIV-associated cryptococcosis in France (1985–2001): comparison of the pre- and post-HAART erasAIDS20041855556215090810
   PubMed Web of Science ®Google Scholar
• KnightFRMackenzieDWEvansBGPorterKBarrettNJWhiteGCIncreasing incidence of cryptococcosis in the United KingdomJ Infect1993271851918228302
   PubMed Web of Science ®Google Scholar
• CurrieBPCasadevallAEstimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York CityClin Infect Dis199419102910337888529
   PubMed Web of Science ®Google Scholar
• JarvisJNHarrisonTSHIV-associated cryptococcal meningitisAIDS2007212119212918090038
   PubMed Web of Science ®Google Scholar
• KisengePRHawkinsATMaroVPLow CD4 count plus coma predicts cryptococcal meningitis in TanzaniaBMC Infect Dis200773917493266
   PubMed Web of Science ®Google Scholar
• van EldenLJWalenkampAMLipovskyMMDeclining number of patients with cryptococcosis in the Netherlands in the era of highly active antiretroviral therapyAIDS2000142787278811125898
   PubMed Web of Science ®Google Scholar
• MocroftAVellaSBenfieldTLChanging patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study GroupLancet1998352172517309848347
   PubMed Web of Science ®Google Scholar
• PalellaFJJrDelaneyKMMoormanACDeclining morbidity and mortality among patients with advanced human immunodefciency virus infection. HIV Outpatient Study InvestigatorsN Engl J Med19983388538609516219
   PubMed Web of Science ®Google Scholar
• GarveyLWinstonAWalshJHIV-associated central nervous system diseases in the recent combination antiretroviral therapy eraEur J Neurol20111852753421159073
   PubMed Web of Science ®Google Scholar
• MirzaSAPhelanMRimlandDThe changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992–2000Clin Infect Dis20033678979412627365
   PubMed Web of Science ®Google Scholar
• Joint United Nations Programme on HIV/AIDSWorld AIDS Day Report – 2011GenevaUNAIDS2011 Available from: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/jc2216_worldaidsday_report_2011_en.pdfAccessed February 13, 2014
   Google Scholar
• GordonSBWalshALChapondaMBacterial meningitis in Malawian adults: pneumococcal disease is common, severe, and seasonalClin Infect Dis200031535710913396
   PubMed Web of Science ®Google Scholar
• HeydermanRSGangaidzoITHakimJGCryptococcal meningitis in human immunodeficiency virus-infected patients in Harare, ZimbabweClin Infect Dis1998262842899502443
   PubMed Web of Science ®Google Scholar
• HakimJGGangaidzoITHeydermanRSImpact of HIV infection on meningitis in Harare, Zimbabwe: a prospective study of 406 predominantly adult patientsAIDS2000141401140710930155
   PubMed Web of Science ®Google Scholar
• SchutteCMVan der MeydenCHMagaziDSThe impact of HIV on meningitis as seen at a South African academic hospital (1994 to 1998)Infection2000283710697783
   PubMed Web of Science ®Google Scholar
• BissonGPLukesJThakurRMtoniIMacGregorRRCryptococcus and lymphocytic meningitis in BotswanaS Afr Med J20089872472519113056
   PubMed Web of Science ®Google Scholar
• HarlingGOrrellCWoodRHealthcare utilization of patients accessing an African national treatment programBMC Health Serv Res200778017555564
   PubMed Web of Science ®Google Scholar
• NissapatornVLessons learned about opportunistic infections in Southeast AsiaSoutheast Asian J Trop Med Public Health20083962564119058599
   PubMedGoogle Scholar
• LeimannBCKoifmanRJCryptococcal meningitis in Rio de Janeiro State, Brazil, 1994–2004Cad Saude Publica2008242582259219009138
   PubMed Web of Science ®Google Scholar
• LortholaryOPoizatGZellerVLong-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapyAIDS2006202183219117086058
   PubMed Web of Science ®Google Scholar
• AntinoriSRidolfoAFasanMAIDS-associated cryptococcosis: a comparison of epidemiology, clinical features and outcome in the pre- and post-HAART eras. Experience of a single centre in ItalyHIV Med20091061119125961
   PubMed Web of Science ®Google Scholar
• KambuguAMeyaDBRheinJOutcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapyClin Infect Dis2008461694170118433339
   PubMed Web of Science ®Google Scholar
• van der HorstCMSaagMSCloudGATreatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials GroupN Engl J Med199733715219203426
   PubMed Web of Science ®Google Scholar
• BicanicTMeintjesGWoodRFungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazoleClin Infect Dis200745768017554704
   PubMed Web of Science ®Google Scholar
• BicanicTWoodRMeintjesGHigh-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trialClin Infect Dis20084712313018505387
   PubMed Web of Science ®Google Scholar
• PitisuttithumPTansuphasawadikulSSimpsonAJHowePAWhiteNJA prospective study of AIDS-associated cryptococcal meningitis in Thailand treated with high-dose amphotericin BJ Infect20014322623311869059
   PubMed Web of Science ®Google Scholar
• SloanDJDedicoatMJLallooDGTreatment of cryptococcal meningitis in resource limited settingsCurr Opin Infect Dis20092245546319587589
   PubMed Web of Science ®Google Scholar
• HayRJMackenzieDWCampbellCKPhilpotCMCryptococcosis in the United Kingdom and the Irish Republic: an analysis of 69 casesJ Infect1980213227185913
   PubMed Web of Science ®Google Scholar
• HusainSWagenerMMSinghNCryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcomeEmerg Infect Dis2001737538111384512
   PubMed Web of Science ®Google Scholar
• SlavinMAChenSCCryptococcosis, lymphoproliferative disorders and modern day chemotherapy regimensLeuk Lymphoma20135444945023035788
   PubMed Web of Science ®Google Scholar
• HageCAWoodKLWiner-MuramHTWilsonSJSarosiGKnoxKSPulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapyChest20031242395239714665529
   PubMed Web of Science ®Google Scholar
• NathDSKandaswamyRGruessnerRSutherlandDEDunnDLHumarAFungal infections in transplant recipients receiving alemtuzumabTransplant Proc20053793493615848579
   PubMed Web of Science ®Google Scholar
• BrattonEWEl HusseiniNChastainCAComparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplantPLoS One20127e4358222937064
   PubMed Web of Science ®Google Scholar
• NeofytosDFishmanJAHornDEpidemiology and outcome of invasive fungal infections in solid organ transplant recipientsTranspl Infect Dis20101222022920113459
   PubMed Web of Science ®Google Scholar
• SunHYAlexanderBDLortholaryOUnrecognized pretransplant and donor-derived cryptococcal disease in organ transplant recipientsClin Infect Dis2010511062106920879857
   PubMed Web of Science ®Google Scholar
• BaddleyJWSchainDCGupteAATransmission of Cryptococcus neoformans by organ transplantationClin Infect Dis201152e94e9821220771
   PubMed Web of Science ®Google Scholar
• SinghNHuprikarSBurdetteSDMorrisMIBlairJEWheatLJDonor-derived fungal infections in organ transplant recipients: guidelines of the American Society of Transplantation, infectious diseases community of practiceAm J Transplant2012122414242822694672
   PubMed Web of Science ®Google Scholar
• SunHYWagenerMMSinghNCryptococcosis in solid-organ, hematopoietic stem cell, and tissue transplant recipients: evidence-based evolving trendsClin Infect Dis2009481566157619402789
   PubMed Web of Science ®Google Scholar
• PappasPGAlexanderBDAndesDRInvasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)Clin Infect Dis2010501101111120218876
   PubMed Web of Science ®Google Scholar
• KontoyiannisDPMarrKAParkBJProspective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) databaseClin Infect Dis2010501091110020218877
   PubMed Web of Science ®Google Scholar
• NguyenMHHusainSClancyCJOutcomes of central nervous system cryptococcosis vary with host immune function: results from a multi-center, prospective studyJ Infect20106141942620732350
   PubMed Web of Science ®Google Scholar
• DromerFMathoulinSDupontBLaporteAEpidemiology of cryptococcosis in France: a 9-year survey (1985–1993). French Cryptococcosis Study GroupClin Infect Dis19962382908816134
   PubMed Web of Science ®Google Scholar
• SinghNAlexanderBDLortholaryOCryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortalityJ Infect Dis200719575676417262720
   PubMed Web of Science ®Google Scholar
• ShaariahWMoradZSuleimanABCryptococcosis in renal transplant recipientsTransplant Proc199224189818991412904
   PubMed Web of Science ®Google Scholar
• ChenSSorrellTNimmoGEpidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study GroupClin Infect Dis20003149950810987712
   PubMed Web of Science ®Google Scholar
• MwabaPMwansaJChintuCClinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditionsPostgrad Med J20017776977311723315
   PubMed Web of Science ®Google Scholar
• RotheCSloanDJGoodsonPA prospective longitudinal study of the clinical outcomes from cryptococcal meningitis following treatment induction with 800 mg oral fluconazole in Blantyre, MalawiPLoS One20138e6731123840659
   PubMed Web of Science ®Google Scholar
• SeatonRAVermaNNaraqiSWembriJPWarrellDAThe effect of corticosteroids on visual loss in Cryptococcus neoformans var gattii meningitisTrans R Soc Trop Med Hyg19979150529093628
   PubMed Web of Science ®Google Scholar
• SeatonRAVermaNNaraqiSWembriJPWarrellDAVisual loss in immunocompetent patients with Cryptococcus neoformans var gattii meningitisTrans R Soc Trop Med Hyg19979144499093627
   PubMed Web of Science ®Google Scholar
• LesserRLSimonRMLeonHSiegelNCryptococcal meningitis and internal ophthalmoplegiaAm J Ophthalmol197987682687443340
   PubMed Web of Science ®Google Scholar
• KestelynPTaelmanHBogaertsJOphthalmic manifestations of infections with Cryptococcus neoformans in patients with the acquired immunodefciency syndromeAm J Ophthalmol19931167217278250075
   PubMed Web of Science ®Google Scholar
• LallooDFisherDNaraqiSCryptococcal meningitis (C. neoformans var gattii) leading to blindness in previously healthy Melanesian adults in Papua New GuineaQ J Med1994873433498041866
   PubMedGoogle Scholar
• TrachtenbergJDKambuguADMcKellarMThe medical management of central nervous system infections in Uganda and the potential impact of an algorithm-based approach to improve outcomesInt J Infect Dis20071152453017512773
   PubMed Web of Science ®Google Scholar
• MoosaMYCoovadiaYMCryptococcal meningitis in Durban, South Africa: a comparison of clinical features, laboratory findings, and outcome for human immunodeficiency virus (HIV)-positive and HIV-negative patientsClin Infect Dis1997241311349114135
   PubMed Web of Science ®Google Scholar
• KabandaTSiednerMJKlausnerJDMuzooraCBoulwareDRPoint-of-care diagnosis and prognostication of cryptococcal meningitis with the cryptococcal antigen lateral flow assay on cerebrospinal fluidClin Infect Dis20145811311624065327
   PubMed Web of Science ®Google Scholar
• RugemalilaJMaroVPKapandaGNdaroAJJarvisJNCryptococcal antigen prevalence in HIV-infected Tanzanians: a cross-sectional study and evaluation of a point-of-care lateral flow assayTrop Med Int Health2013181075107923937699
   PubMed Web of Science ®Google Scholar
• McMullanBJHallidayCSorrellTCClinical utility of the cryptococcal antigen lateral flow assay in a diagnostic mycology laboratoryPLoS One20127e4954123166705
   PubMed Web of Science ®Google Scholar
• JarvisJNPercivalABaumanSEvaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitisClin Infect Dis2011531019102321940419
   PubMed Web of Science ®Google Scholar
• World Health OrganizationRapid Advice: Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-Infected Adults, Adolescents and ChildrenGenevaWHO2011 Available from: http://whqlibdoc.who.int/publications/2011/9789241502979_eng.pdfAccessed February 13, 2014
   Google Scholar
• BrouwerAERajanuwongAChierakulWCombination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trialLancet20043631764176715172774
   PubMed Web of Science ®Google Scholar
• BicanicTMuzooraCBrouwerAEIndependent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patientsClin Infect Dis20094970270919613840
   PubMed Web of Science ®Google Scholar
• AndesDPharmacokinetics and pharmacodynamics of antifungalsInfect Dis Clin North Am20062067969716984875
   PubMed Web of Science ®Google Scholar
• DenningDWHopeWWTherapy for fungal diseases: opportunities and prioritiesTrends Microbiol20101819520420207544
   PubMed Web of Science ®Google Scholar
• CornelyOAMaertensJBresnikMLiposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)Clin Infect Dis2007441289129717443465
   PubMed Web of Science ®Google Scholar
• HamillRJSobelJDEl-SadrWComparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safetyClin Infect Dis20105122523220536366
   PubMed Web of Science ®Google Scholar
• LeendersACReissPPortegiesPLiposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitisAIDS199711146314719342068
   PubMed Web of Science ®Google Scholar
• ChenSCCryptococcosis in Australasia and the treatment of cryptococcal and other fungal infections with liposomal amphotericin BJ Antimicrob Chemother200249Suppl 1576111801583
   PubMed Web of Science ®Google Scholar
• BicanicTOgdenDWhitneyLLoyseAJarvisJBritish HIV Association opportunistic infection guidelines: in defence of amphotericin B deoxycholateHIV Med20121363663723051823
   PubMed Web of Science ®Google Scholar
• PappasPGChetchotisakdPLarsenRAA phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitisClin Infect Dis2009481775178319441980
   PubMed Web of Science ®Google Scholar
• RajasinghamRMeyaDBBoulwareDRIntegrating cryptococcal antigen screening and pre-emptive treatment into routine HIV careJ Acquir Immune Defic Syndr201259e85e9122410867
   PubMed Web of Science ®Google Scholar
• JacksonATNussbaumJCPhulusaJA phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitisAIDS2012261363137022526517
   PubMed Web of Science ®Google Scholar
• ButlerEKBoulwareDRBohjanenPRMeyaDBLong term 5-year survival of persons with cryptococcal meningitis or asymptomatic subclinical antigenemia in UgandaPLoS One20127e5129123251485
   PubMed Web of Science ®Google Scholar
• DayJNChauTTLallooDGCombination antifungal therapy for cryptococcal meningitisN Engl J Med20133682522252323802521
   PubMed Web of Science ®Google Scholar
• LoyseADromerFDayJLortholaryOHarrisonTSFlucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungalJ Antimicrob Chemother2013682435244423788479
   PubMed Web of Science ®Google Scholar
• O’ConnorLLivermoreJSharpADPharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patientsJ Infect Dis201320835136123599314
   PubMed Web of Science ®Google Scholar
• DromerFBernede-BauduinCGuillemotDLortholaryOMajor role for amphotericin B-flucytosine combination in severe cryptococcosisPLoS One20083e287018682846
   PubMed Web of Science ®Google Scholar
• SaagMSCloudGAGraybillJRA comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study GroupClin Infect Dis19992829129610064246
   PubMed Web of Science ®Google Scholar
• AndesDPascualAMarchettiOAntifungal therapeutic drug monitoring: established and emerging indicationsAntimicrob Agents Chemother200953243418955533
   PubMed Web of Science ®Google Scholar
• BicanicTWoodRBekkerLGDarderMMeintjesGHarrisonTSAntiretroviral roll-out, antifungal roll-back: access to treatment for cryptococcal meningitisLancet Infect Dis2005553053116122672
   PubMed Web of Science ®Google Scholar
• LoyseAThangarajHEasterbrookPCryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countriesLancet Infect Dis20131362963723735626
   PubMed Web of Science ®Google Scholar
• MuzooraCKKabandaTOrtuGShort course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitisJ Infect201264768122079502
   PubMed Web of Science ®Google Scholar
• LoyseAWilsonDMeintjesGComparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitisClin Infect Dis20125412112822052885
   PubMed Web of Science ®Google Scholar
• RajasinghamRRolfesMABirkenkampKEMeyaDBBoulwareDRCryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysisPLoS Med20129e100131623055838
   PubMed Web of Science ®Google Scholar
• Mayanja-KizzaHOishiKMitaraiSCombination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDSClin Infect Dis199826136213669636863
   PubMed Web of Science ®Google Scholar
• SchaarsCFMeintjesGAMorroniCPostFAMaartensGOutcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazoleBMC Infect Dis2006611816846523
   PubMed Web of Science ®Google Scholar
• LongleyNMuzooraCTaseeraKDose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern UgandaClin Infect Dis2008471556156118990067
   PubMed Web of Science ®Google Scholar
• NussbaumJCJacksonANamarikaDCombination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in MalawiClin Infect Dis20105033834420038244
   PubMed Web of Science ®Google Scholar
• SudanALivermoreJHowardSJPharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpointsAntimicrob Agents Chemother2013572793280023571544
   PubMed Web of Science ®Google Scholar
• MilefchikELealMAHaubrichRFluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitisMed Mycol20084639339518415850
   PubMed Web of Science ®Google Scholar
• St George’s University of London (UK)Advancing Cryptococcal meningitis Treatment for Africa: Oral fluconazole plus flucytosine or one week amphotericin B-based therapy vs two weeks amphotericin B-based therapy for initial treatment of HIV-associated cryptococcal meningitis Available from: http://www.controlled-trials.com/ISRCTN45035509. ISRCTN identifier: ISRCTN45035509Accessed February 28, 2014
   Google Scholar
• BozzetteSALarsenRAChiuJA placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodefciency syndrome. California Collaborative Treatment GroupN Engl J Med19913245805841992319
   PubMed Web of Science ®Google Scholar
• PowderlyWGSaagMSCloudGAA controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study GroupN Engl J Med19923267937981538722
   PubMed Web of Science ®Google Scholar
• CollettGParrishAFluconazole donation and outcomes assessment in cryptococcal meningitisS Afr Med J20079717517617440660
   PubMed Web of Science ®Google Scholar
• JarvisJNMeintjesGWilliamsZRebeKHarrisonTSSymptomatic relapse of HIV-associated cryptococcal meningitis in South Africa: the role of inadequate secondary prophylaxisS Afr Med J201010037838220526411
   PubMed Web of Science ®Google Scholar
• MussiniCPezzottiPMiroJMDiscontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational studyClin Infect Dis20043856557114765351
   PubMed Web of Science ®Google Scholar
• VibhagoolASungkanuparphSMootsikapunPDiscontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized studyClin Infect Dis2003361329133112746781
   PubMed Web of Science ®Google Scholar
• MartínezEGarcía-ViejoMAMarcosMADiscontinuation of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients responding to highly active antiretroviral therapyAIDS2000142615261711101078
   PubMed Web of Science ®Google Scholar
• RollotFBossiPTubianaRDiscontinuation of secondary prophylaxis against cryptococcosis in patients with AIDS receiving highly active antiretroviral therapyAIDS2001151448144911504971
   PubMed Web of Science ®Google Scholar
• SeddonJMangeyaNMillerRFCorbettELFerrandRARecurrence of cryptococcal meningitis in HIV-infected patients following immune reconstitutionInt J STD AIDS20092027427519304977
   PubMed Web of Science ®Google Scholar
• SinghNLortholaryOAlexanderBDAn immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipientsClin Infect Dis2005401756176115909263
   PubMed Web of Science ®Google Scholar
• SinghNPerfectJRImmune reconstitution syndrome associated with opportunistic mycosesLancet Infect Dis2007739540117521592
   PubMed Web of Science ®Google Scholar
• SinghNLortholaryOAlexanderBDAntifungal management practices and evolution of infection in organ transplant recipients with Cryptococcus neoformans infectionTransplantation2005801033103916278582
   PubMed Web of Science ®Google Scholar
• Morera-LópezYTorres-RodríguezJMJiménez-CabelloTBaró-TomásTCryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazoleMed Mycol20054350551016320494
   PubMed Web of Science ®Google Scholar
• ChongHSDaggRMalikRChenSCarterDIn vitro susceptibility of the yeast pathogen cryptococcus to fluconazole and other azoles varies with molecular genotypeJ Clin Microbiol2010484115412020844209
   PubMed Web of Science ®Google Scholar
• SmithRMNguyenTAHaHTPrevalence of cryptococcal antigenemia and cost-effectiveness of a cryptococcal antigen screening program – VietnamPLoS One20138e6221323626792
   PubMed Web of Science ®Google Scholar
• BeyeneTWoldeamanuelYAsratDAyanaGBoulwareDRComparison of cryptococcal antigenemia between antiretroviral naive and antiretroviral experienced HIV positive patients at two hospitals in EthiopiaPLoS One20138e7558524124498
   PubMed Web of Science ®Google Scholar
• AlemuASKempkerRRTennaAHigh prevalence of cryptococcal antigenemia among HIV-infected patients receiving antiretroviral therapy in EthiopiaPLoS One20138e5837723469276
   PubMed Web of Science ®Google Scholar
• FrenchNGrayKWateraCCryptococcal infection in a cohort of HIV-1-infected Ugandan adultsAIDS2002161031103811953469
   PubMed Web of Science ®Google Scholar
• LiechtyCASolbergPWereWAsymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural UgandaTrop Med Int Health20071292993517697087
   PubMed Web of Science ®Google Scholar
• GovenderNPChettyVRoyMPhased implementation of screening for cryptococcal disease in South AfricaS Afr Med J201210291491723498036
   PubMed Web of Science ®Google Scholar
• JarvisJNHarrisonTSLawnSDMeintjesGWoodRClearySCost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South AfricaPLoS One20138e6928823894442
   PubMed Web of Science ®Google Scholar
• JarvisJNLawnSDVogtMBanganiNWoodRHarrisonTSScreening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South AfricaClin Infect Dis20094885686219222372
   PubMed Web of Science ®Google Scholar
• MeyaDBManabeYCCastelnuovoBCost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count ≤100 cells/microL who start HIV therapy in resource-limited settingsClin Infect Dis20105144845520597693
   PubMed Web of Science ®Google Scholar
• JarvisJNGovenderNChillerTCryptococcal antigen screening and preemptive therapy in patients initiating antiretroviral therapy in resource-limited settings: a proposed algorithm for clinical implementationJ Int Assoc Physicians AIDS Care (Chic)20121137437923015379
   PubMedGoogle Scholar
• MeyerACKendiCKPennerJAThe impact of routine cryptococcal antigen screening on survival among HIV-infected individuals with advanced immunosuppression in KenyaTrop Med Int Health20131849550323368667
   PubMed Web of Science ®Google Scholar
• ChangLWPhippsWTKennedyGERutherfordGWAntifungal interventions for the primary prevention of cryptococcal disease in adults with HIVCochrane Database Syst Rev2005CD00477316034947
   PubMed Web of Science ®Google Scholar
• Parkes-RatanshiRWakehamKLevinJPrimary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trialLancet Infect Dis20111193394121982529
   PubMed Web of Science ®Google Scholar
• ApisarnthanarakAMundyLMThe impact of primary prophylaxis for cryptococcosis on fluconazole resistance in Candida speciesJ Acquir Immune Defc Syndr200847644645
   PubMed Web of Science ®Google Scholar
• BicanicTBrouwerAEMeintjesGRelationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar puncturesAIDS20092370170619279443
   PubMed Web of Science ®Google Scholar
• GraybillJRSobelJSaagMDiagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment GroupsClin Infect Dis200030475410619732
   PubMed Web of Science ®Google Scholar
• PappasPGManaging cryptococcal meningitis is about handling the pressureClin Infect Dis20054048048215668875
   PubMed Web of Science ®Google Scholar
• DammertPBustamanteBTiconaETreatment of cryptococcal meningitis in Peruvian AIDS patients using amphotericin B and fluconazoleJ Infect20085726026518707764
   PubMed Web of Science ®Google Scholar
• de VediaLArechavalaACalderonMIRelevance of intracranial hypertension control in the management of Cryptococcus neoformans meningitis related to AIDSInfection2013411073107724122543
   PubMed Web of Science ®Google Scholar
• WijewardanaIJarvisJNMeintjesGHarrisonTSBicanicTLarge volume lumbar punctures in cryptococcal meningitis clear cryptococcal antigen as well as lowering pressureJ Infect20116348448621930156
   PubMed Web of Science ®Google Scholar
• ManosuthiWSungkanuparphSChottanapundSTemporary external lumbar drainage for reducing elevated intracranial pressure in HIV-infected patients with cryptococcal meningitisInt J STD AIDS20081926827118482948
   PubMed Web of Science ®Google Scholar
• WoodworthGFMcGirtMJWilliamsMARigamontiDThe use of ventriculoperitoneal shunts for uncontrollable intracranial hypertension without ventriculomegally secondary to HIV-associated cryptococcal meningitisSurg Neurol200563529531 discussion 531–53215936373
   PubMedGoogle Scholar
• NewtonPNThai leHTipNQA randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitisClin Infect Dis20023576977212203177
   PubMed Web of Science ®Google Scholar
• HaddowLJColebundersRMeintjesGCryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitionsLancet Infect Dis20101079180221029993
   PubMed Web of Science ®Google Scholar
• LawnSDHarriesADAnglaretXMyerLWoodREarly mortality among adults accessing antiretroviral treatment programmes in sub-Saharan AfricaAIDS2008221897190818784453
   PubMed Web of Science ®Google Scholar
• BissonGPNthobatsongRThakurRThe use of HAART is associated with decreased risk of death during initial treatment of cryptococcal meningitis in adults in BotswanaJ Acquir Immune Defc Syndr200849227229
   Web of Science ®Google Scholar
• KlotzSAAziz MohammedAGirmai WoldemichaelMWorku MitkuMHandrichMImmune reconstitution inflammatory syndrome in a resource-poor settingJ Int Assoc Physicians AIDS Care (Chic)2009812212719258527
   PubMedGoogle Scholar
• LawnSDBekkerLGMyerLOrrellCWoodRCryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programmeAIDS2005192050205216260920
   PubMed Web of Science ®Google Scholar
• MurdochDMVenterWDFeldmanCVan RieAIncidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective studyAIDS20082260161018317001
   PubMed Web of Science ®Google Scholar
• FrenchMAHIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisalClin Infect Dis20094810110719025493
   PubMed Web of Science ®Google Scholar
• LongleyNHarrisonTSJarvisJNCryptococcal immune reconstitution inflammatory syndromeCurr Opin Infect Dis201326263423242412
   PubMed Web of Science ®Google Scholar
• LortholaryOFontanetAMemainNMartinASitbonKDromerFIncidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in FranceAIDS2005191043104915958835
   PubMed Web of Science ®Google Scholar
• BicanicTMeintjesGRebeKImmune reconstitution infammatory syndrome in HIV-associated cryptococcal meningitis: a prospective studyJ Acquir Immune Defic Syndr20095113013419365271
   PubMed Web of Science ®Google Scholar
• LeshoEEvidence base for using corticosteroids to treat HIV-associated immune reconstitution syndromeExpert Rev Anti Infect Ther2006446947816771623
   PubMedGoogle Scholar
• ChangCDorasamayAElliottJHIV+ patients with CM who attain CSF sterility pre-cART commencement experience improved outcomes in the first 24 weeksPoster presented at: 19th Conference on Retroviruses and Opportunistic InfectionsMarch 5–8, 2012Seattle, WA
   Google Scholar
• JacksonAvan der HorstCNew insights in the prevention, diagnosis, and treatment of cryptococcal meningitisCurr HIV/AIDS Rep2012926727722763808
   PubMed Web of Science ®Google Scholar
• ManosuthiWChottanapundSSungkanuparphSMortality rate of early versus deferred initiation of antiretroviral therapy in HIV-1-infected patients with cryptococcal meningitisJ Acquir Immune Defic Syndr20084850850918614933
   PubMed Web of Science ®Google Scholar
• ZolopaAAndersenJPowderlyWEarly antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trialPLoS One20094e557519440326
   PubMed Web of Science ®Google Scholar
• BissonGPMolefiMBellamySEarly versus delayed antiretroviral therapy and cerebrospinal fluid fungal clearance in adults with HIV and cryptococcal meningitisClin Infect Dis2013561165117323362285
   PubMed Web of Science ®Google Scholar
• MakadzangeATNdhlovuCETakarindaKEarly versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-Saharan AfricaClin Infect Dis2010501532153820415574
   PubMed Web of Science ®Google Scholar
• BoulwareDMeyaDMuzooraCART initiation within the first 2 weeks of cryptococcal meningitis is associated with higher mortality: a multisite randomized trialPoster presented at: 20th Conference on Retroviruses and Opportunistic InfectionsMarch 3–6, 2013Atlanta, GA
   Google Scholar